COX-2 inhibitors: managing comorbidities in primary care

Br J Cardiol 2005;12:392-3 Leave a comment
Click any image to enlarge
Authors:

The recent withdrawal of rofecoxib, a COX-2 inhibitor,
has focussed attention on the use of COX-2
inhibitors and other non-steroidal anti-inflammatory
drugs (NSAIDs) in patients with cardiovascular disease.

THERE ARE CURRENTLY NO COMMENTS FOR THIS ARTICLE - LEAVE A COMMENT
back to top